Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,300 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Comment le bénéfice par action récent de CRL se compare-t-il aux attentes ?
Le bénéfice par action le plus récent de Charles River Laboratories International Inc est de $3.02, battement les attentes de $2.76.
Comment les revenus de Charles River Laboratories International Inc CRL se sont-ils comportés au dernier trimestre ?
Les revenus de Charles River Laboratories International Inc pour le dernier trimestre s'élèvent à $3.02
Quelle est l'estimation des revenus pour Charles River Laboratories International Inc ?
Selon 13 analystes de Wall Street, l'estimation des revenus de Charles River Laboratories International Inc varie de $1.03B à $921.98M
Quel est le score de qualité des bénéfices pour Charles River Laboratories International Inc ?
Charles River Laboratories International Inc a un score de qualité des bénéfices de B+/45.645683. Le score est basé sur quatre dimensions : rentabilité, croissance, génération de trésorerie et allocation de capital, et effet de levier.
Quand Charles River Laboratories International Inc publie-t-elle ses résultats ?
Le prochain rapport de résultats de Charles River Laboratories International Inc est attendu pour 2026-11-03
Quels sont les bénéfices attendus de Charles River Laboratories International Inc ?
Les bénéfices attendus de Charles River Laboratories International Inc s'élèvent à $985.44M, selon les analystes de Wall Street.
Charles River Laboratories International Inc a-t-elle dépassé les attentes en matière de bénéfices ?
Les bénéfices récents de Charles River Laboratories International Inc s'élèvent à $1.0B, ne bat pas les attentes.